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Tuberculosis (TB) is the second leading cause of death by infectious disease worldwide. The only available TB 
vaccine is the Bacille Calmette-Guerin (BCG). However, parenterally administered Mycobacterium bovis BCG 
vaccine confers only limited immune protection from pulmonary tuberculosis in humans. There is a need for 
developing effective boosting vaccination strategies. AdAg85A, an adenoviral vector expressing the 
mycobacterial protein Ag85A, is a new tuberculosis vaccine candidate, and has shown promising results in pre-
clinical studies and phase I trial. This adenovirus vectored vaccine is produced using HEK 293 cell culture. 
 
 Here we report on the optimization of cell culture conditions, scale-up of production and purification of the 
AdAg85A at different scales. Four commercial serum-free media were evaluated under various conditions for 
supporting the growth of HEK293 cell and production of AdAg85A. A culturing strategy was employed to take 
advantages of two culture media with respective strengths in supporting the cell growth and virus production, 
which enabled to maintain virus productivity at higher cell densities and resulted in more than two folds of 
increases in culture titer. The production of AdAg85A was successfully scaled up and validated at 60L 
bioreactor under the optimal conditions. 
 
The AdAg85A generated from the 3L and 60L bioreactor runs was purified through several purification steps. 
More than 98% of total cellular proteins was removed, over 60% of viral particles was recovered after the 
purification process, and purity of AdAg85A was similar to that of the ATCC VR-1516 Ad5 standard. Vaccination 
of mice with the purified AdAg85A demonstrated a very good level of Ag85A-specific antibody responses. The 
optimized production and purification conditions were transferred to a GMP facility for manufacturing of 
AdAg85A for generation of clinical grade material to support clinical trials. 
 
